Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 14/20 | 0.53 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.53 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5443035 | 0.80 | KCNN3 (0.52) | KCNN3KCNN1KCNN2PDE10AMAPKAPK2 | |
| SCHEMBL13998582 | 0.80 | KCNN3 (0.55) | KCNN3KCNN1KCNN2PDE10AMAPKAPK2 | |
| SCHEMBL4318891 | 0.75 | PDE10A (0.49) | KCNN3KCNN1KCNN2PDE10A | |
| SCHEMBL14427346 | 0.75 | CDK2 (0.47) | KCNN3KCNN1KCNN2PDE10A | |
| SCHEMBL5451854 | 0.74 | KCNN3 (0.64) | KCNN3KCNN1KCNN2PDE10AMAPKAPK2 | |
| SCHEMBL13998581 | 0.73 | KCNN3 (0.53) | KCNN3KCNN1KCNN2PDE10A | |
| SCHEMBL31602095 | 0.72 | KCNN3 (0.52) | KCNN3KCNN1KCNN2PDE10AMAPKAPK2 | |
| SCHEMBL14158199 | 0.70 | PDE10A (0.61) | KCNN3KCNN1KCNN2PDE10APRKAB2 | |
| SCHEMBL13117302 | 0.69 | KCNN3 (0.80) | KCNN3KCNN1KCNN2PDE10A | |
| SCHEMBL14427342 | 0.69 | CCNE1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | claimed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | claimed |
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060595-A1 | Novel fused heterocyclic compound and use thereof | JUN, CHUK, RELA | KCNN3 3885/4885KCNN1 3422/4885KCNN2 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.